Could a common diabetes drug stop diabetes after kidney transplant?

NCT ID NCT07682350

First seen Jul 02, 2026 ยท Last updated Jul 02, 2026

Summary

This trial tests whether taking dapagliflozin (Forxiga) for 12 months can prevent post-transplant diabetes in kidney transplant recipients who do not have diabetes. The study includes 184 adults who recently received a kidney transplant and are on standard immunosuppressive therapy. Participants are randomly assigned to receive either dapagliflozin or a placebo, and researchers monitor diabetes development, kidney function, and safety over a year.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Dapagliflozin (Forxiga)
What this could lead to
If it works, this could offer a way to prevent diabetes after kidney transplant, helping patients avoid a lifelong condition and protecting their new kidney.
What could go wrong
This is a Phase 2 trial with 184 participants, so results are preliminary. The drug may not reduce diabetes risk or could cause side effects like urinary infections or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT RECIPIENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Nephrology and Endocrinology.

    Copenhagen, 2100, Denmark

  • Department of Nephrology, Odense University Hospital

    Odense, 5000, Denmark

  • Department of Renal Medicine

    Aarhus, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.